Abbvie Inc. vs Kymera Therapeutics, Inc.
ABBV vs KYMR — side-by-side comparison from reported financials. ABBV leads 6, KYMR leads 3 of 9 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Kymera Therapeutics, Inc.
KYMR · Healthcare
$112.40+2.84%Strong
| Metric | ABBV | KYMR |
|---|---|---|
| Price | $276.43 | $112.40 |
| Market cap | $488B | $9.35B |
| Revenue (TTM) | $64.4B | $105M |
| Revenue growth | +1.8% | -5.8% |
| Net margin | 9.8% | -285.3% |
| Free cash flow | $18.2B | -$238M |
| Net cash (debt) | ($56.2B) | $766M |
| 1-year price return | +19.8% | +97.1% |
| P/E | 77.4 | — |
| P/E vs own history (cheap-side %) | 23% | — |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | -22% |
| Altman Z-score | 2.33 | 47.67 |
| CV checks passed | 9 of 11 | 4 of 11 |
| Employees | 57,000 | 273 |
Full résumé-style profiles: ABBV CV · KYMR CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.